Beam Therapeutics Inc. (BEAM)
BEAM Stock Price Chart
Explore Beam Therapeutics Inc. interactive price chart. Choose custom timeframes to analyze BEAM price movements and trends.
BEAM Company Profile
Discover essential business fundamentals and corporate details for Beam Therapeutics Inc. (BEAM) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Feb 2020
Employees
393.00
Website
https://www.beamtx.comCEO
John M. Evans
Description
Beam Therapeutics Inc., a biotechnology company, develops precision genetic medicines for patients suffering from serious diseases in the United States. The company is developing BEAM-101 for the treatment of sickle cell disease and beta thalassemia; BEAM-102 for the treatment of sickle cell disease; and BEAM-201, an allogeneic chimeric antigen receptor T cell for the treatment of relapsed/refractory T-cell acute lymphoblastic leukemia; and BEAM-301, a liver-targeted development candidate for the treatment of patients with Glycogen Storage Disease Type Ia. It also develops therapies for alpha-1 antitrypsin deficiency; ocular diseases; and other liver, muscle, and central nervous system disorders. The company has an alliance with Boston Children's Hospital; a research and clinical trial collaboration agreement with Magenta Therapeutics, Inc.; license agreement with Sana Biotechnology, Inc.; and a research collaboration with the Institute of Molecular and Clinical Ophthalmology Basel. It also has a research collaboration agreement with Pfizer Inc. and Apellis Pharmaceuticals, Inc.; and collaboration and license agreement with Verve Therapeutics, Inc. The company was incorporated in 2017 and is based in Cambridge, Massachusetts.
BEAM Financial Timeline
Browse a chronological timeline of Beam Therapeutics Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 4 May 2026
Upcoming earnings on 23 Feb 2026
Upcoming earnings on 4 Nov 2025
EPS estimate is -$1.02, while revenue estimate is $13.57M.
Earnings released on 5 Aug 2025
EPS came in at -$1.00 surpassing the estimated -$1.04 by +3.85%, while revenue for the quarter reached $8.47M , missing expectations by -26.62%.
Earnings released on 6 May 2025
EPS came in at -$1.24 falling short of the estimated -$1.11 by -11.71%, while revenue for the quarter reached $7.47M , missing expectations by -51.86%.
Earnings released on 25 Feb 2025
EPS came in at -$1.09 surpassing the estimated -$1.25 by +12.80%, while revenue for the quarter reached $30.07M , beating expectations by +82.51%.
Earnings released on 5 Nov 2024
EPS came in at -$1.17 falling short of the estimated -$1.13 by -3.54%, while revenue for the quarter reached $14.27M , missing expectations by -5.64%.
Earnings released on 6 Aug 2024
EPS came in at -$1.11 surpassing the estimated -$1.13 by +1.77%, while revenue for the quarter reached $11.77M , missing expectations by -14.26%.
Earnings released on 7 May 2024
EPS came in at -$1.21 surpassing the estimated -$1.45 by +16.55%, while revenue for the quarter reached $7.41M , missing expectations by -56.33%.
Earnings released on 27 Feb 2024
EPS came in at $1.73 surpassing the estimated -$1.01 by +271.29%, while revenue for the quarter reached $316.19M , beating expectations by +1.59K%.
Earnings released on 8 Nov 2023
EPS came in at -$1.22 surpassing the estimated -$1.37 by +10.95%, while revenue for the quarter reached $17.19M , missing expectations by -13.65%.
Earnings released on 8 Aug 2023
EPS came in at -$1.08 surpassing the estimated -$1.38 by +21.74%, while revenue for the quarter reached $20.12M , beating expectations by +11.45%.
Earnings released on 10 May 2023
EPS came in at -$1.33 surpassing the estimated -$1.36 by +2.21%, while revenue for the quarter reached $24.21M , beating expectations by +71.93%.
Earnings released on 28 Feb 2023
EPS came in at -$0.54 surpassing the estimated -$1.32 by +59.09%, while revenue for the quarter reached $20.04M , beating expectations by +57.61%.
Earnings released on 7 Nov 2022
EPS came in at -$1.56 falling short of the estimated -$1.30 by -20.00%, while revenue for the quarter reached $15.80M , beating expectations by +120.95%.
Earnings released on 9 Aug 2022
EPS came in at -$1.02 surpassing the estimated -$1.08 by +5.56%, while revenue for the quarter reached $16.65M , beating expectations by +98.48%.
Earnings released on 9 May 2022
EPS came in at -$1.01 surpassing the estimated -$1.10 by +8.18%, while revenue for the quarter reached $8.43M , missing expectations by -80.90%.
Earnings released on 28 Feb 2022
EPS came in at -$0.85 surpassing the estimated -$1.02 by +16.67%, while revenue for the quarter reached $51.07M , beating expectations by +496.37%.
Earnings released on 8 Nov 2021
EPS came in at -$0.42 surpassing the estimated -$0.78 by +46.15%, while revenue for the quarter reached $763.00K , missing expectations by -32.48%.
Earnings released on 10 Aug 2021
EPS came in at -$0.95 falling short of the estimated -$0.58 by -63.79%, while revenue for the quarter reached $6.00K , beating expectations by +11.62%.
Earnings released on 11 May 2021
EPS came in at -$3.35 falling short of the estimated -$0.72 by -365.28%, while revenue for the quarter reached $6.00K , missing expectations by -56.03%.
Earnings released on 15 Mar 2021
EPS came in at -$0.72 falling short of the estimated -$0.70 by -2.86%, while revenue for the quarter reached $6.00K .
Earnings released on 10 Nov 2020
EPS came in at -$0.69 falling short of the estimated -$0.57 by -21.05%, while revenue for the quarter reached $6.00K , beating expectations by +30.24%.
BEAM Stock Performance
Access detailed BEAM performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.